Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 FY- Text added to 2019 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
BoD, bore, buyer, Canndoc, Cloverleaf, cum, disagreement, distinction, Dot, Dow, dual, economy, Electra, epidemic, Ernest, ESOP, expedient, Haldor, Hill, Kryon, laude, Mofet, monetize, OnJanuary, outbreak, pandemic, Rotem, sector, sentiment, Shapira, spread, TAT, Team, Turgemen, whProspective, Yalon, Yalonserve, Young
Removed:
abandonment, abatacept, ABC, acetate, Actelion, Actemra, Alex, Amgen, anifrolumab, Anthera, atacicept, base, Bashan, Biogen, blind, blisibimod, boutique, call, Celgene, CFO, combining, comparable, Concurrently, convalescence, death, double, Economist, eighteen, Electronic, Eli, ending, Energy, epratuzumab, exceeded, failed, forigerimod, Formula, FVOCI, Gamatronic, GSK, Hospital, IDB, Immupharma, initiating, Innovative, intention, Invion, irrevocable, JD, KPMG, Leumi, Lilly, lupuzor, Matrix, MedImmune, Merck, multinational, officially, overhead, Pretium, provisional, PRTL, randomized, regained, Renewable, Resolve, Rituxan, Roche, Room, RSLV, sensitive, Serono, space, Squibb, Strasbourg, tabalumab, tolerability, venture, vested, VP, Washington, Yeshiva
Valuein 2018 FY filing- Value in 2019 FY filing
Original filings
Filing view